Apexigen uses antibodies derived from rabbits to develop therapies for diseases that are difficult to treat. LSIPR found out how it protects its novel technologies.
Second and further medical use claims provide companies and patent lawyers with interesting opportunities, as Caroline Pallard explains.
In a global league, Canada’s biotech industry would be respectably mid table. LSIPR talks to Andrew Casey, president of industry association BIOTECanada, about how the organisation is trying to take it to the next level.
Stem cells are seen by many as the great hope for medical research in the years to come. LSIPR spoke to Nicholas Seay, chief technology officer at Cellular Dynamics, about the importance of IP in this field.
The first US court decision applying the Myriad decision has landed, and it makes for interesting reading, as Antoinette Konski reports.
Ethical considerations plus the ambiguity of the Biotech Directive are factors influencing the patentability of totipotent stem cells, says Andrew Sanderson.
New guidelines for the examination of biotechnology inventions in Brazil provide useful support for applicants, as Gabriel Di Blasi and Alexandre Santos explain.
Frances Salisbury and Lindsey Woolley look at the complex business of patenting agricultural products in Europe.
When the US Supreme Court decided in favour of Monsanto in its case against a soybean farmer, it clarified the patent status of certain self-replicating technologies. In Europe, the result would probably have been the same, say Steven Zeman and Heike Vogelsang-Wenke.
When it comes to plants, European courts have been occupied with various debates over salad. Margreet van Heuvel and Bart Swinkels take a look.